Equity
€91,136 ▲ 53.6%
PHARMADVANCE has made a profit without a break since 2020.
PHARMADVANCE
Lifetime
9 annual accounts with figures on one time axispeak €344,477 (2021)
€299,297▼ 8.9%
lowest -€136,995 (2017)
€43,820▲ 280%
peak €91,136 (2025)
€91,136▲ 53.6%
€975,360▼ 5.7%
peak 4.1 FTE (2022)
4 FTE▲ 5.3%
Board5 names since 2017
2 directorsBLUESTONE and 1 other
Owners
Documentsfilings and deeds
08-07-202623 days before the deadline
2025abbreviated format
Result from €11,539 to €43,820Equity from €59,315 to €91,136Cash from €10,185 to €49,161
Key points
from the 2025 annual accountsTurnover
≈ €1.1m estimated
The accounts state no turnover.
Debts
€975,360 91% of the balance sheet
Financial debts 26%Suppliers 46%Taxes and wages 4%Other 24%
Of this, €726,360 falls due within a year.
Filings
9 annual accounts 8 late
The 2022 accounts came latest: 90 days after the end of the period.
At the same address
6 companies
Position in the sector
8.5%
Lower solvency than 80% of companies in retail trade. Sector median 36.6% · 12,853 companies.
Checked score
54
Fair
Financially stronger than 41% of micro companies in retail trade (NACE 47)
Probability in this band: 1.5% to 4.2%
Bankruptcy probability within 12 months
1.9% Moderate
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,275 companies (NACE 47, micro).
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 5.9%
01-2025: 5.9%● unchanged vs 12-2024
02-2025: 6.0%▲ +0.1 percentage points vs 01-2025
03-2025: 6.1%▲ +0.1 percentage points vs 02-2025highest value
04-2025: 5.5%▼ -0.6 percentage points vs 03-2025
05-2025: 5.5%● unchanged vs 04-2025
06-2025: 5.3%▼ -0.2 percentage points vs 05-2025
07-2025: 5.0%▼ -0.3 percentage points vs 06-2025
08-2025: 6.1%▲ +1.1 percentage points vs 07-2025
09-2025: 2.7%▼ -3.4 percentage points vs 08-2025
10-2025: 2.7%● unchanged vs 09-2025
11-2025: 2.7%● unchanged vs 10-2025
12-2025: 2.7%● unchanged vs 11-2025
01-2026: 2.6%▼ -0.1 percentage points vs 12-2025
02-2026: 2.6%● unchanged vs 01-2026
03-2026: 2.5%▼ -0.1 percentage points vs 02-2026
04-2026: 2.5%● unchanged vs 03-2026
05-2026: 2.5%● unchanged vs 04-2026
06-2026: 2.6%▲ +0.1 percentage points vs 05-2026
07-2026: 3.0%▲ +0.4 percentage points vs 06-2026
08-2026: 1.9%▼ -1.1 percentage points vs 07-2026lowest value
09-2026: 1.9%● unchanged vs 08-2026lowest value
10-2026: 1.9%● unchanged vs 09-2026lowest value
11-2026: 1.9%● unchanged vs 10-2026lowest value
Financial strengthWeak
Score breakdown
raises risk
Equity €91,136 (8.5% of total assets)
1 of the last 3 accounts late
Sector: Retail trade (NACE 47)
Liquidity: current ratio 1.03, cash €49,161
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 25% of them on solvency, 18% on liquidity, 32% on profitability and 87% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the moderate class on 30-06-2025, 2.4% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 1,251 companies had the same profile as PHARMADVANCE has now. Each dot stands for 4 companies, two years later.
94.4%
were still trading
2.7%
stopped another way
2.6%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PHARMADVANCE itself: 1.9% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,251 companies, not a prediction for PHARMADVANCE. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €4,500 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.03 (1.04 in 2024), below the usual 1.5. Short-term debt is 68.1% and cash 4.6% of total assets. 91.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
raises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 12853 sector peers (2025).
NBB · sector comparisonPosition among 12853 sector peers
Solvency
better than 19%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 9 filingsDeviation from the deadline
2025
23 days early
2024
21 days late
2023
84 days late
2022
90 days late
2021
33 days late
2020
61 days late
2019
17 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 40 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 2 September (4 of the last 5 accounts filed within 56 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0671818337
Changes of role: BLUESTONE (director) and HP PHARMA (director)
Permanent representatives: Paul RANSART and Stéphanie THOMAES · “1) l'exploitation d'officines pharmaceutiques dans le respect des règles édictées par l'Ordre des…” (deed in French) · Director discharge: BLUESTONE · General meeting of 10-07-2023 · Gazette deed
2 directors appointed, 2 resignations
Resignations: Paul RANSART and PHARMACOACH · Permanent representatives: Stephanie THOMAES and Paul RANSART · Appointments: BLUESTONE and HP PHARMA · General meeting of 16-06-2022 · Gazette deed
New establishment in Leuze-en-Hainaut
Pharmacie de la Grand-Place, Grand-Place 15
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMADVANCE Chièvres | €1.1m | €299,297 | 8.5% | 4 |
| PHARMACIE KERKOVRE Comblain-au-Pont | €0.9m | €356,053 | 11.7% | 3.8 |
| Mentover Antwerp | €1.0m | €360,699 | 4.6% | 3.2 |
| PHARMACIE DE l'EDEN Montigny-le-Tilleul | €1.0m | €394,694 | 46.7% | 3.5 |
| Pharmaplus Grand Place Tournai | €0.9m | €426,998 | 32.3% | 3.9 |
| PHARMACIE DEPREZ Charleroi | €1.5m | €306,093 | 41.3% | 3.2 |
| PHARMACIE LAMBLIN-LAMBOT Chapelle-lez-Herlaimont | €1.3m | €385,076 | 43.8% | 4 |
These companies have the same main activity as PHARMADVANCE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €896,000 and €1.5m, founded between 2016 and 2019.
Official details
Source: KBO- Status
- Active since 24-02-2017Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment units
- 2.262.124.5287950 Chièvres, since 24-02-2017
- 2.273.198.9587900 Leuze-en-Hainaut, since 01-05-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2023
Annual accounts 2025
- €1.1m▼ 2.5%
- Employeeson 31-12-2025
- 4=
- Filing
- Filed on 08-07-2026, 23 days before the end of the filing period
Insights on PHARMADVANCE
PHARMADVANCE files the abbreviated format. That format states no turnover. The gross margin rose from €133,526 in 2017 to €299,297 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMADVANCE
- What is the company number of PHARMADVANCE?
- The company number of PHARMADVANCE is 0671.818.337. The VAT number is the same number with BE in front: BE 0671.818.337.
- Where is PHARMADVANCE based?
- The registered office is at Rue de l'Eglise 48, 7950 Chièvres.Company details
- What does PHARMADVANCE do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMADVANCE?
- PHARMADVANCE is a private limited company (BV).
- When was PHARMADVANCE founded?
- PHARMADVANCE was founded on 24-02-2017.
- Is PHARMADVANCE still active?
- Yes, PHARMADVANCE is an active enterprise in the KBO register.
- How many employees does PHARMADVANCE have?
- PHARMADVANCE had an average of 4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of PHARMADVANCE?
- The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €299,297 and 47 comparable companies (NACE 477). It probably lies between €810,000 and €1.7m.
- Is PHARMADVANCE profitable?
- In financial year 2025, PHARMADVANCE made a profit of €43,820.
- Where can I find the annual accounts of PHARMADVANCE?
- PHARMADVANCE filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMADVANCE due?
- PHARMADVANCE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.